Top Biotech Companies in Singapore (105)
Carcell Biopharma ("Carcell") is a global biotech company launched by EVX Ventures. With an innovative “hub-and-spoke” business model, Carcell accelerates innovations in and translation of next-generation cell and gene therapies. Carcell has two lead technology platforms. The first technological platform creates engineered red blood cells (eRBC) for allogeneic cell therapy against autoimmune diseases and cancer. The second technological platform is...
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and...
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or...
Agilent Technologies's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry and company materials consistently place Agilent among the top global players in analytical instrumentation—especially in chromatography and mass spectrometry—and as a frequent short‑list vendor for regulated and R&D labs. Recognition such as Instrument Business Outlook’s “Company of the Year” supports this standing.
Diversified Revenue Streams: The portfolio spans instruments, software/informatics, consumables, and services (Agilent CrossLab), with end‑to‑end workflows and specialty CDMO contributions providing multiple revenue levers. This breadth increases switching costs and drives recurring revenue that helps balance capital‑equipment cycles.
Resilient & Sustainable Growth: After a FY2024 decline, revenue returned to growth in FY2025 and continued in Q1 FY2026, with guidance pointing to mid‑single‑digit core growth and margin expansion. CrossLab’s steady growth and an instrument replacement cycle are cited as continuing supports.
For 85 years, PerkinElmer has pushed the boundaries of science from food to health to the environment. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate...
PerkinElmer's Top Stability & Growth Strengths
Strong Market Position & Advantage: Colleagues are often seen as operating from a top-tier competitive position in applied, food, and environmental analytical markets, including a significant presence in food testing and leadership in multivendor lab services via OneSource. The large global installed base and asset footprint are portrayed as reinforcing defensibility and ongoing demand for services and support.
Innovation-Driven Growth: Colleagues are often seen as sustaining relevance through ongoing product launches and upgrades such as digital PCR systems, updated LIMS software, and new analytical platforms aimed at emerging needs like PFAS detection and battery applications. The continued cadence of new instruments and workflow solutions is positioned as a key growth lever alongside services and consumables.
Investor Backing & Capital Strength: Colleagues are often seen as supported by private-equity ownership under New Mountain Capital and described with a substantial valuation, suggesting access to capital and an explicit mandate to scale. Recent acquisitions (e.g., Covaris and Project Farma) are framed as capability-building moves consistent with a funded expansion strategy.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture...
Thermo Fisher Scientific's Top Stability & Growth Strengths
Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.
Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.
Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.
Biomatch specializes in connecting top talent with leading companies in the life sciences sector, including pharmaceuticals, biotechnology, and medical technology. They offer tailored recruitment solutions, conduct candidate assessments, and aim to find the right job match for candidates and experts for companies.
The Lee Kong Chian School of Medicine (LKCMedicine) trains doctors with a focus on patient-centered care, integrating precision medicine, Artificial Intelligence (AI) in healthcare, and medical humanities into its undergraduate medical degree program.
We are a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Our technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Our programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted...
Bio-Rad now offers over 11,000 antibodies and related reagents for various applications such as flow cytometry. We also provide highly validated Precision Ab™ antibodies for western blotting.
Princeton Biopartners is a best-in-class provider of integrated consulting solutions to the life sciences sector. Our mission is to improve the evidence base, accessibility, and impact of biomedical innovations through strategic advisory, software, and our venture fund. We pride ourselves on establishing long-term client relationships and are dedicated to addressing pain points via integrated and transformative projects. Setting new standards...
FMC Corporation is an US-based chemical manufacturing company producing solutions for the agricultural, textile, and healthcare industries. FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC’s innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture –...
Qritive makes cancer diagnosis fast, cheap, and accurate. Qritive develops AI-powered solutions that enable histopathologic diagnosisof cancer at scale. Our clinical-decision support system for pathologists unlocks efficiency and quality gain in diagnosis, which results in better patient outcome. It includes AI Modules, an Image Management System platform (Pantheon), and a network of pathologists on-demand for services (annotations, 2nd opinion...) Our digital...
Novotech is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services.
Systemic Bio is a 3D Systems company based in Houston, Texas, focused on the development of vascularized organ models made out of hydrogels and human cells to be used for drug discovery and development.
Tricon Energy is a global leader in the trade and distribution of industrial chemicals, fuels, plastic intermediates, and fertilizers. Founded in 1996, the company's mission is to sustainably and efficiently connect the world with essential goods by providing superior logistics, risk management, financing, and market intelligence services to its clients and suppliers worldwide.
Rand Technology is a leading global independent distributor of electronic components and a sophisticated, full-service technology hardware supply chain company offering comprehensive services for NPI, production, and global asset recovery.
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt...
Oxford Nanopore Technologies's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.
Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.
Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.
Lion TCR is a clinical-stage biotechnology company dedicated to the continued development and commercialization of our TCR-T therapy.
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery...
